Phase III data showed it met the primary pain relief endpoint compared to placebo 6/08

Began enrolling patients in a Phase III study 11/07

Completed enrollment in its Phase III trial 11/07; Phase III data showed it does not increase a patient's risk of developing cardiac arrhythmias, or an irregular heart beat 1/08; Phase III data showed it greatly improved walking ability 6/08

Acadia started the first of two pivotal Phase III trials 6/07; began its second Phase III trial 3/08

Started a Phase III trial in glioblastoma multiforme and a Phase IIb/IIIa trial in chemotherapy-naive patients with advanced pancreatic cancer 08/07

Recruited the final patient in a Phase III trial combining product with radiation to treat children and adolescents 08/07

FDA accepted for review the NDA 1/08

FDA agreed to an SPA for a Phase III trial in combination with ara-C 6/07; started patient dosing in pivotal Phase III trial 10/07

Dosed the first patient in a Phase III trial 4/08

Both Phase III trials have reached the 118th relapse event 10/07

Accrued 210 patients in Phase III trial 11/06; Vion suspended enrollment and further patient treatment pending a review of all data based on a recommendation of a data safety monitoring board 5/07; FDA lifted a clinical hold on the Phase III trial originally imposed because the advantage seen appeared to be compromised by the mortality observed in the study 1/08

A pivotal Phase III trial is under way testing it as first-line therapy in chemotherapy-naive patients with recurrent Stage III or IV disease 1/07

Phase II/III data showed it significantly increased time to tumor progression and had a positive influence on overall survival time 7/07

FDA approved an SPA for a Phase III trial with 120 patients expected to begin later this year 9/08

Monitors for pivotal Phase III trial recommended continuing study to completion 6/06; FDA granted orphan designation 9/06; results from Phase III trial delayed because 258th death has not yet occurred 11/06; Phase III data showed drug missed statistical significance on its primary endpoint 2/07

FDA granted orphan designation in this indication 2/06; Phase III trial did not meet endpoint of improving survival vs. palliative chemotherapy or best supportive care, and a BLA filing was no longer planned 6/06

Drug missed its primary endpoints of overall survival in two Phase III studies 12/06; FDA initiated a clinical hold after Phase III data detailed the failures of the ASSIST-1, -2 and -3 trials; FDA converted full clinical hold to a partial hold, allowing patients to continue receiving treatment 6/07; FDA removed the partial hold on clinical trials 10/07; stopped enrolling patients due to the interruption of a five-month clinical hold that may have caused study to miss its mark 10/08

Began a pivotal Phase III trial 11/07; met its target of 630 patients for a pivotal study, the SYMMETRYSM trial 2/09; company halted development due to a higher than expected death rate 2/09

Dacogen failed to show a significant survival advantage compared to best supportive care in a Phase III trial 7/08